GHRH vs GHRP: Which Receptor Does Each Act On?
Research Use Only. This article discusses compounds and methods studied in preclinical research and laboratory contexts. Products supplied by Stacked BioLabs are intended for in vitro research and laboratory use only — not for human consumption, animal consumption outside approved preclinical research, therapeutic application, or clinical use.
GHRH binds its own G-protein coupled receptor, GHRHR, in hypothalamic nuclei and in pituitary somatotroph cells. GHRPs act at the separate GH secretagogue receptor, and ghsr-knockout mouse studies confirmed that these secretagogues are ghrelin mimetics. In adults, GHRPs released more GH than GHRH, and their combination was synergistic.
GHRH is a 44-amino acid peptide primarily expressed in the hypothalamus, where it binds its G-protein coupled receptor (GHRHR) in the arcuate (ARC), ventromedial (VMH) and periventricular (PeN) nuclei, and its highest non-brain expression is in the somatotroph cells of the pituitary[1]. The GH secretagogue receptor (GHS-R) was identified separately by expression cloning as a previously unknown G-protein coupled receptor, expressed predominantly in brain, pituitary gland and pancreas[2]. A 2026 review of peptides modulating the growth hormone–insulin-like growth factor-1 (GH–IGF-1) axis lists GHRH analogs and growth hormone secretagogues (GHS) among its peptide groups, alongside a GH fragment and IGF-1 analogs[4].
What are GHRH and GHRP, and which receptor does each act on?
Human GHRH was originally extracted from two pancreatic tumors in patients with acromegaly, and consists of a 44-residue amidated peptide or its C-terminal-shortened derivatives[5]. Rat GHRH is a 43-residue peptide sharing about 70% homology with the human sequence, located mainly in the arcuate nucleus of the hypothalamus[5].
RNA sequencing places GHRH expression predominantly in the hypothalamus in humans, with some basal ganglia presence, and extends it to further central nervous system (CNS) regions in other species[1].
GHRPs are synthetic molecules with reproducible GH-releasing activity in humans, acting at both the pituitary and the hypothalamic level, where specific receptors have been located[3]. Lead GHS structures were identified on function, because neither the receptor nor the ligand controlling GH pulse amplitude was known at the time[2].
| Feature | GHRH class | GHRP / GHS class |
|---|---|---|
| Receptor | GHRHR, a G-protein coupled receptor in the ARC, VMH and PeN hypothalamic nuclei and in pituitary somatotrophs[1] | GHS-R, a G-protein coupled receptor expressed predominantly in brain, pituitary gland and pancreas[2] |
| Endogenous ligand | GHRH, a 44-amino acid peptide primarily expressed in the hypothalamus[1] | ghrelin, acting via GHS-R1a on GHRH neurons[1] |
| Named compounds | sermorelin, tesamorelin, CJC-1295 with DAC, CJC-1295 without DAC[4] | GHRP-2, GHRP-6, hexarelin, ipamorelin[4] |
| Somatostatin link | in obese patients, compounds thought to inhibit hypothalamic somatostatin release improved, though did not normalize, the GH response to GHRH[6] | in human studies, GHRP activity was not further increased by such compounds and was only blunted by somatostatin stimulators[3] |
Which compounds are studied as GHRH analogs?
Sermorelin, tesamorelin, CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC are grouped as GHRH analogs in a review of peptides modulating the GH–IGF-1 axis[4].
In the rat, pulsatile GH release is principally a consequence of pulsatile hypothalamic GHRH release, which appears to be associated with a transient suppression of somatostatin release[5]. In many animal species, exogenous GHRH specifically increased circulating GH, and in the long term it may increase growth[5].
In normal man, several analogs of GHRH acted as sensitive and specific stimuli to GH release, although there may be a variable prolactin response, usually of small magnitude[5]. Many children with GH deficiency — idiopathic, radiation-induced or secondary to hypothalamopituitary tumors — responded to GHRH with an acute rise in serum GH[5].
GH deficiency often reflects hypothalamic GHRH deficiency, and in aged subjects the decline in GH/IGF-I axis function reflects a reduction in hypothalamic function, evidenced by the preserved releasable pool of pituitary GH[7].
Which peptides act as GHRPs or ghrelin mimetics?
GHRP-6 is listed with GHRP-2, hexarelin and ipamorelin as a GHS in the same 2026 review[4]. That review treats the GH fragment AOD9604 (hGH 176-191) and IGF-1 analogs such as pegylated mechano growth factor (PEG-MGF) and IGF-1 Long R3 (IGF-1 LR3) as categories separate from both the GHRH analogs and the GHS[4].
Studies in ghsr-knockout mice confirmed that the GHS are ghrelin mimetics[2]. GH pulse amplitude could be increased by four possible mechanisms: increasing GHRH release, amplifying GHRH signaling in somatotrophs of the anterior pituitary gland, reducing somatostatin release and antagonizing somatostatin receptor signaling[2].
What does research report when the two classes are combined?
Ghrelin acts via GHS-R1a on GHRH neurons[1]. In adults, GHRPs released more GH than GHRH did, while their combination produced a synergistic effect, indicating at least partially different mechanisms of action[3]. In the same human work, normal activity of GHRH-secreting neurons was needed to reach the full GH-releasing effect of GHRPs[3].
In obese patients, GHRP-6 and hexarelin elicited GH responses greater than those evoked by GHRH, yet still lower than those seen in lean subjects[6]. In these patients, GHRH combined with GHRP-6 was the largest GH-releasing stimulus known, and the response again stayed below that of lean subjects[6].
Why does somatostatin make this pairing a research question?
A 2025 review sets out competing models of GH pulse timing: early ones proposed alternating GHRH and somatostatin bursts, while others implicate somatostatin as the primary regulator of pulse timing[1].
In human studies, the GH-releasing activity of GHRPs was not further increased by substances acting through inhibition of hypothalamic somatostatin, and was only blunted by substances that stimulate hypothalamic somatostatin release[3]. Even free fatty acids and exogenous somatostatin, which act directly on somatotrophs, did no more than blunt the GHRP response in the same studies, read there as antagonism of somatostatin activity at both the pituitary and the hypothalamic level[3]. The reduced GH response to GHRPs in the elderly is probably due mainly to concomitant GHRH hypoactivity and somatostatinergic hyperactivity[3].
GH secretion, spontaneous or evoked by provocative stimuli, is markedly blunted in obese patients, including responses to stimuli acting at the hypothalamus and to direct somatotroph stimulation by exogenous GHRH[6]. A somatostatin hypertone, a GHRH deficiency and a functional failure of the somatotroph have each been proposed as contributing factors in these patients, and the defect appears to be secondary and probably adaptive, since it is completely reversed by normalization of body weight[6].
How does this class logic shape CJC-1295 and ipamorelin research stacks?
Pairings built on CJC-1295 without DAC and ipamorelin draw one compound from the GHRH analog group and one from the GHS group of that 2026 classification[4].
The same review stratifies these peptides into evidence tiers, running from regulatory-grade randomized trial data to a complete absence of human studies[4]. A 2020 review of GH secretagogues in hypogonadal males describes a paucity of data on the clinical effects of sermorelin, GHRP-2, GHRP-6, ibutamoren and ipamorelin, which it frames as an opening for future investigation[8].
Frequently asked questions
Does leptin influence GH release?
Evidence in rodents suggests that leptin, the product of the adipocyte-specific ob gene, exerts a stimulating effect on GH release. In obese patients, high leptin and low GH serum levels coexist, which may fit a concept of leptin resistance if the rodent finding also holds in people.
Do GHRP responses vary with sex or age?
In human studies, the GH-releasing effect of GHRPs did not depend on gender but underwent age-related variations. Gonadal steroids appeared to influence the activity of GHRPs only in childhood.
How does the peripheral IGF-I axis look in obesity research?
In obese patients, high free IGF-I, low IGF-binding proteins 1 and 2 (IGFBP-1 and IGFBP-2), normal or high IGFBP-3 and increased GH binding protein (GHBP) circulating levels have been described. In the same patients, drugs that block lipolysis and lower serum free fatty acids (NEFA) significantly improved GH secretion.
Have GHRPs been studied in short stature and in obesity?
GHRPs increased GH release in children with idiopathic short stature, in GH deficiency and in obese patients, in whom somatotroph function is reduced.
What else did cloning the GHS receptor identify?
The cloned GHS-R was exploited to identify an endogenous agonist, ghrelin, and a partial agonist, adenosine. In old mice, the same body of work induced restoration of thymic function.
References
- Hypothalamic GHRH. Rev Endocr Metab Disord. 2025. PMID: 39913072
- Development of growth hormone secretagogues. Endocr Rev. 2005. PMID: 15814848
- Age-related growth hormone-releasing activity of growth hormone secretagogues in humans. Acta Paediatr Suppl. 1997. PMID: 9401552
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026. PMID: 42395176
- Growth hormone releasing hormone. Clin Endocrinol Metab. 1986. PMID: 2429796
- Growth hormone in obesity. Int J Obes Relat Metab Disord. 1999. PMID: 10193871
- GHRH and GH secretagogues: clinical perspectives and safety. Pediatr Endocrinol Rev. 2004. PMID: 16456487
- Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020. PMID: 32257855
Important Notice — Research Use Only All compounds discussed in this article are described in the context of published laboratory, preclinical and clinical research. Products supplied by Stacked BioLabs are intended for in vitro research and laboratory use only. They are not for human consumption, are not for animal consumption outside of approved preclinical animal research, are not intended to diagnose, treat, cure, or prevent any disease, and have not been approved by the FDA for any therapeutic application. This article makes no claims regarding efficacy, safety, or appropriateness of these compounds for any application outside controlled research settings. Researchers using these compounds are responsible for compliance with all applicable laws, regulations, and institutional review requirements. Information in this article does not constitute medical, veterinary, or scientific advice for any application outside controlled research settings. Read the full Research Use Only policy.